Medicare Duplicate Lab Test Denials and Modifier 91: What Labs Need to Know
Short answer: Medicare does not pay for duplicate laboratory tests unless they are medically necessary, as CMS restated in its October 1, 2026 MLN Connects newsletter. Medicare contractors deny duplicates that lack necessity. Modifier 91 identifies a medically necessary repeat of the same test on the same day, and it does not cover reruns, confirmations, or repeat germline testing.
What did CMS say about duplicate lab tests on October 1, 2026?
The October 1, 2026 edition of MLN Connects, the CMS provider newsletter, carried a short item titled "Laboratory Testing: Medicare Denies Duplicate Tests." Its core statement is plain: Medicare does not pay for duplicate tests unless they are medically necessary. CMS tells providers to review the contents of a panel before ordering individual tests that the panel already includes, and says Medicare Administrative Contractors will deny duplicate tests that lack medical necessity. Its example is a second vitamin D test, which is not covered unless clinically justified.
The newsletter points to CPT modifier 91, the repeat clinical diagnostic laboratory test modifier, for cases where a repeat is medically necessary, and to the Medicare Claims Processing Manual, Chapter 16. The item is a reminder of existing policy rather than a new rule, but reminders from CMS tend to precede tighter contractor edits and post-payment review attention, so it is worth treating as a prompt to audit your own order and billing patterns.
For molecular and genetic testing labs, the practical issue is that duplication can happen in three different places: inside a single order, across orders on the same day, and across years of a patient's history. Each has a different rule, and modifier 91 only addresses one of them.
When does modifier 91 apply?
Noridian Healthcare Solutions, a Medicare Administrative Contractor, describes modifier 91 as the modifier for a laboratory test performed more than once on the same day on the same patient, used to obtain subsequent, multiple test results. It applies to tests paid under the clinical laboratory fee schedule. First Coast Service Options, another contractor, adds the conditions: the same CPT code is ordered for the same beneficiary, the specimen is collected more than once in a single day, and the service is medically necessary.
First Coast also sets out the billing mechanics. Submit all same-day services on one claim, report each test as a separate line with a quantity of one, and append 91 to the repeat procedure code. Its example uses potassium, CPT 84132, billed as one line of 84132 and a second line of 84132-91. Providers must document the use of the modifier in the medical record.
When is modifier 91 the wrong answer?
Noridian lists the exclusions explicitly. Modifier 91 is not for use when a standard HCPCS code already describes the series of results, such as glucose tolerance tests or evocative and suppression testing. It is also not for tests rerun to confirm initial results, tests repeated because of specimen or equipment problems, or any other situation where a normal, one-time, reportable result is all that is required. Noridian cites the Medicare Claims Processing Manual, Publication 100-04, Chapter 16, Section 100.5.1.
That list matters for molecular labs. A repeat run triggered by a failed extraction, a low-quality specimen, a QC failure, or a confirmatory assay is a lab-side event, and the contractor guidance says it is not billable under modifier 91. Labs that append 91 to recover the cost of a rerun are using the modifier outside its stated purpose, which is a compliance exposure rather than a denial-management tactic.
How do duplicates differ for germline genetic tests?
Modifier 91 is a same-day concept. Duplication across a patient's history is governed by coverage policy, and for germline testing the MolDX Repeat Germline Testing policy is explicit. As summarized from the Medicare Coverage Database listing (LCD 38351), with an effective date of December 30, 2021, the policy treats repeat testing of identical genetic content in the same patient as not covered. It describes duplicative testing as any laboratory test that investigates the same germline genetic content, for the same genetic information, that has already been tested, and it sets a limit of one lifetime unit of service per specific test.
The reasoning given is biological: germline alleles do not change over time, so repeating the same test does not by its nature provide new clinical information. The policy does leave room. Gene panels that contain some previously untested content with established clinical utility may be reasonable and necessary, and the policy allows for technological advances that require a different approach to the same genomic regions.
Read together, the two policies close off the usual workaround. A repeat germline test is not rescued by a modifier, because modifier 91 addresses same-day repeats of tests where multiple results are needed, and a one-time germline result does not fit that description. The question that decides coverage is whether the new order contains genetic content that has not already been tested.
What should labs and revenue cycle teams do now?
Start with order intake. Build a check that compares each incoming requisition against the patient's prior tests with your lab, flagging identical CPT or PLA codes, overlapping gene content, and individual tests that a panel on the same requisition already contains. CMS's own advice is to review panel contents, and that is the cheapest control available because it works before a specimen is accessioned.
Next, audit your use of modifier 91. Pull every claim line carrying it over the past year and confirm that each one reflects a same-day repeat with a documented medical-necessity reason, and that none reflects a rerun, a confirmation, or a specimen or equipment problem. Align this audit with the broader genetic testing denials review so that duplicate-test denials are tracked as their own category rather than lumped under generic medical-necessity denials.
Then address the ordering side. Ordering clinicians often do not know that a patient was tested at another laboratory years ago. A short requisition field asking whether prior germline testing was performed, and where, gives your team the information it needs to decide whether to proceed, narrow the panel, or request a different test. The same discipline supports Medicare coverage for genetic testing documentation more generally.
Finally, connect this to your edit and code maintenance cycle. CMS also publishes quarterly updates to the laboratory NCD edit software, covered in our October 2026 lab NCD edit update, and an MLN Matters article on the January 2027 update was listed in the same October 1 newsletter. Duplicate-test controls and diagnosis-code edits should live on the same quarterly checklist. For lab workflows that check coverage criteria before an order is finalized, explore the platform at ScreenMyGene.
Frequently asked questions
Does Medicare pay for a repeat lab test?
Only when it is medically necessary. CMS states Medicare does not pay for duplicate tests unless they are medically necessary, and contractors deny duplicates that lack necessity. When a repeat is necessary, modifier 91 identifies it, supported by documentation in the medical record.
What is CPT modifier 91 used for?
Modifier 91 reports a medically necessary repeat of the same clinical laboratory test, on the same patient, on the same day, when the specimen is collected more than once. Each test is reported on a separate line with a quantity of one, with the modifier appended to the repeat line.
Can I use modifier 91 when I rerun a test to confirm a result?
No. Noridian guidance says modifier 91 is not for reruns to confirm initial results, for specimen or equipment problems, or for any situation where one normal reportable result is all that is required. Those reruns are not separately billable under the modifier.
Does Medicare cover repeat germline genetic testing?
Generally not for identical content. The MolDX Repeat Germline Testing policy treats testing of the same germline genetic content as not covered, with a one lifetime unit limit per specific test. Panels with some previously untested, clinically useful content may be reasonable and necessary.
How can labs reduce duplicate-test denials?
Check each requisition against prior testing and panel contents before accessioning, capture prior germline testing history from the ordering clinician, and audit every claim line using modifier 91. Track duplicate-test denials as a separate category so patterns by client or test become visible.
This article is educational and intended for laboratory and revenue cycle professionals. It is not legal, coding, or reimbursement advice, and it does not replace payer or CMS documents. Verify all policies against current CMS and contractor publications before billing.
Sources: CMS, MLN Connects Newsletter, October 1, 2026; Noridian Healthcare Solutions, Modifier 91 guidance (citing Medicare Claims Processing Manual, Pub. 100-04, Ch. 16, Sec. 100.5.1); First Coast Service Options, "Utilizing modifier 91: Repeat clinical laboratory tests"; MolDX Repeat Germline Testing policy, Medicare Coverage Database LCD 38351 (effective 12/30/2021).